(INNS)
SIMRIDARLIMAB(INNC)
IMMUNOGLOBULIN (G1_L-KAPPA)_VH-VH-H-CH2-CH3, ANTI-[HOMO SAPIENS CD47 (LEUKOCYTE SURFACE ANTIGEN CD47, INTEGRIN ASSOCIATED PROTEIN, IAP, MER6, OA3] AND ANTI-[HOMO SAPIENS CD274 (PROGRAMMED CELL DEATH 1 LIGAND 1, B7H1, B7-H1, PDL1, PD-L1, PDCD1L1, B7 HOMOLOG 1)], HOMO SAPIENS AND HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA1 HEAVY CHAIN HOMO SAPIENS ANTI-CD47 (1-444) [VH ANTI- CD47 (HOMO SAPIENS IGHV4-59*01 (97.9%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.9] (26-33.51-57.96-104)) (1-115) -HOMO SAPIENS IGHG1*01, G1M17,1, G1V14 CH2 A1.3, A1.2, G1V32 CH3 W22 (CH1 K120 (212) (116-213), HINGE 1-15 (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338), CH3 S10>C (352), D12 (354), L14 (356), T22>W (364) (339-443), CHS K2>DEL (444)) (116-444)], (218-214')-DISULFIDE WITH KAPPA LIGHT CHAIN...; PROPOSED INN: LIST 125, RECOMMENDED INN: LIST 87(WHO)
SIMRIDARLIMABUM(INN)